Mondrian Investment Partners 13F: Cuts Merck (MRK) Stake by $129M

Mondrian Investment Partners trimmed its stake in Merck & Co., Inc. [MRK] by 60.4% during the quarter, according to a Form 13F filing with the SEC on October 23, 2026. The fund sold 889,899 shares, leaving it with 584,046 shares worth about $84,867,724. Merck closed at $145.27 on the day of the filing.

MRK Merck & Co., Inc.

$145.27 ▲ +39.28% year to date

1M 3M YTD

Daily close · Oct 23, 2026

What Changed in Mondrian Investment Partners's Merck & Co., Inc. Position

Mondrian Investment Partners lowered its investment from 1,473,945 shares down to 584,046 shares. That reduction of 889,899 shares reflects a 60.4% cut in the firm's holdings for the drug maker.

Other Institutional Activity in Merck & Co., Inc.

Wilmington Savings Fund Society grew its holdings by 19,001 shares, ending with 204,655 shares worth about $29,738,418.

Merck & Co., Inc. Stock Down 3.1%

Merck shares recently traded around $145.27 as of October 24, 2026. The stock closed at $145.27 on October 23, sitting below its 52-week high of $156.92 and well above its 52-week low of $82.01.

Recent Earnings

Merck reported $66,568,998,912 in trailing-twelve-month revenue with earnings of $1.24 per share. The company posted a net profit margin of 4.8% and a return on equity of 7.0%, with its next earnings report scheduled for October 29, 2026.

Dividend

Merck pays an annual dividend rate of $3.40 per share, giving it a dividend yield of 2.31% based on a dividend payout ratio of 266.7%.

Insider Buying and Selling at Merck & Co., Inc.

Officer Chirfi Guindo sold 15,000 shares on August 6, 2026, at a price of $131.00 for a total of $1,965,000. General Counsel Jennifer L Zachary sold 80,315 shares on August 12, 2026, at $133.46 per share worth $10,718,495. Officer Richard Robert Deluca Jr. sold 45,320 shares on August 12, 2026, valued at $5,942,369. Later, on August 13, 2026, Chirfi Guindo sold another 10,000 shares at $135.00 for a total of $1,350,000.

Analysts Set New Price Targets

On October 5, 2026, JP Morgan maintained its Overweight rating on the stock while raising its price target from $150.00 to $165.00. Morgan Stanley maintained an Overweight rating on October 7, 2026, moving its target from $179.00 down to $177.00. Cantor Fitzgerald maintained a Neutral rating on October 8, 2026, raising its target from $120.00 to $145.00. Citigroup maintained a Neutral rating on October 12, 2026, lifting its target from $125.00 to $145.00. RBC Capital maintained a Sector Perform rating on October 12, 2026, adjusting its target from $150.00 down to $145.00. Overall, the stock carries a consensus buy rating with a mean price target of $158.56 from 25 analysts.

About Merck & Co., Inc.

Merck & Co., Inc. develops human health pharmaceuticals and vaccines across the globe. Its well-known products include treatments and therapies such as Keytruda, Gardasil, and Winrevair. The company employs 73,000 people and is headquartered in Rahway, New Jersey.

Bottom Line

Investors will look to Merck's upcoming earnings report on October 29, 2026, for clues on future pharmaceutical sales and margins. The stock continues to draw steady analyst coverage ahead of that milestone.